Attorney advertisingBriefMass Torts
Federal Dupixent lymphoma lawsuits centralized in New Jersey
Responsible attorney: Lou Schwartz, Schwartz & Associates, PC, Atlanta, Georgia. intake@snalawyers.com
The Judicial Panel on Multidistrict Litigation centralized federal lawsuits alleging that Dupixent (dupilumab), a biologic often prescribed for atopic dermatitis, caused or accelerated cutaneous T-cell lymphoma. The cases are now MDL No. 3180 before Judge Zahid N. Quraishi in the District of New Jersey.
Why it matters. Pretrial proceedings for federal Dupixent cases now run before one judge; the Panel reported 35 actions pending as of September 1, 2026.
Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death. Consult your physician before making any decision regarding prescribed medication or medical treatment. Dupixent remains approved by the U.S. Food and Drug Administration.
Products named here remain subject to FDA approval, clearance or recall status, which can change; check the FDA databases for current status.
Sources
Briefs summarize public developments. Unless stated otherwise, the firm is not counsel in the matters described, and allegations are not findings.
General information, not legal advice. Reading this article or using the intake assistant does not create an attorney-client relationship.